Anthera Pharmaceuticals’ (ANTH) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) in a report released on Tuesday. The firm currently has a $3.00 price objective on the biopharmaceutical company’s stock.
ANTH has been the topic of several other research reports. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 25th. Jefferies Group LLC restated a hold rating and issued a $1.75 target price (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. Finally, ValuEngine lowered shares of Anthera Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Anthera Pharmaceuticals currently has a consensus rating of Hold and an average price target of $5.91.
Shares of Anthera Pharmaceuticals (NASDAQ ANTH) opened at 1.35 on Tuesday. The company’s market cap is $14.72 million. The company has a 50 day moving average of $1.35 and a 200-day moving average of $1.28. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $27.36.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $1.12. Analysts forecast that Anthera Pharmaceuticals will post ($3.68) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Anthera Pharmaceuticals’ (ANTH) “Buy” Rating Reiterated at HC Wainwright” was published by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/22/anthera-pharmaceuticals-anth-buy-rating-reiterated-at-hc-wainwright.html.
A number of institutional investors and hedge funds have recently bought and sold shares of ANTH. Sabby Management LLC increased its stake in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 1,665,655 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 335,595 shares in the last quarter. Finally, UBS Group AG increased its stake in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 33,901 shares in the last quarter. 27.26% of the stock is owned by hedge funds and other institutional investors.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.